← Back
Pharmacology I · Exam 3 · Class of 2028

Pharmacology I Exam 3 Cram Sheet

Lecture 9 (diuretics and heart failure drugs), Lecture 10 (antiarrhythmic drugs) and Lecture 11 (pulmonary infections, asthma and chronic obstructive pulmonary disease), Adam Wood Pharm.D. DABAT. Lectures 12 and 13 are added as delivered. ★ = professor emphasized (from the recording); a star only sets weight and adds no fact the slides lack. Rows marked FLAG or “Current guidelines differ” say where a slide and the pharmacology disagree; the slides are what is tested.

How to use this: this is a condensed, night-before-the-exam reference, not a replacement for the full study guide — it assumes you've already learned the material and just need the highest-yield facts at a glance. If a term feels unfamiliar, go back to the full guide for the explanation.

Diuretics & heart failure · what he stressed

TermWhat you need to know
★★ Mortality or symptoms?His standing rule for this whole lecture: good for MORTALITY → the patient should be on it no matter what; good only for SYMPTOMS → may not be needed all the time. Symptoms only: diuretics and digoxin. Survival: angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers), the three beta blockers, aldosterone antagonists in advanced failure, sacubitril-valsartan, sodium-glucose cotransporter 2 inhibitors.
★★ Know every drug's effect on potassium“You can kill somebody very easily with potassium.” LOWER it: loop diuretics, thiazides, carbonic anhydrase inhibitors. RAISE it: potassium-sparing diuretics, aldosterone antagonists, angiotensin-converting enzyme inhibitors, sacubitril-valsartan. Several drugs on one patient: work out which way the total falls.
★ Where salt goes, water followsDiuretics work by blocking sodium (and usually chloride) reabsorption somewhere along the nephron, and water leaves with it. Too much fluid: volume overload and pulmonary edema. Too little: volume depletion and cardiovascular collapse.
★ Digoxin levelDigoxin has a very narrow therapeutic index and its level is checked. The slide gives a target range; he said he is probably not going to quiz the specific level. Know the narrow index, not the number.
★ Xanthopsia is the digoxin clueYellow-green vision with halos around lights is the classic clue to digoxin toxicity; in his words it is “pathognomonic,” nothing else does that. (Ivabradine also causes halos and brightness, but without the yellow-green tint.) It means check a level right away.
★ Heart failure decision shapeHis rule of thumb: hypertensive patient in decompensated failure → milrinone (it dilates vessels). Hypotensive patient → dobutamine or dopamine. Ask what the blood pressure is.
DosesThis site leaves milligram amounts out; doses are not tested in this course, per the earlier lectures. Timings, routes and clinical thresholds are kept.

Diuretics · the nephron and where each class works

TermWhat you need to know
Why diuretics are dangerousDiuretic = a drug that increases urine flow and/or sodium chloride excretion. A sustained imbalance of sodium chloride intake against loss is fatal: too much gives volume overload and pulmonary edema; too little gives volume depletion and cardiovascular collapse.
★ Diuretic brakingThe kidneys receive about 22% of the cardiac output and fight back against volume loss: sympathetic nervous system and renin-angiotensin-aldosterone system activation, lower blood pressure (less pressure natriuresis), antidiuretic hormone up, renal cell hypertrophy. He called the kidneys “divas.” This is why diuretics show synergy with angiotensin-converting enzyme inhibitors and calcium channel blockers, which blunt those compensations.
Proximal tubule60 to 70% of the filtrate is reabsorbed here (glucose, amino acids, organic solutes; weak acids and bases are secreted into the lumen). Carbonic anhydrase inhibitors work here.
Loop of HenleConcentrates the urine. Descending limb: water leaves the lumen. Ascending limb: 25% of sodium reabsorbed, impermeable to water. Loop diuretics work here.
Distal tubuleAbout 5% of sodium reabsorbed. Thiazide diuretics work here.
Collecting duct2 to 3% of sodium reabsorbed; aldosterone and antidiuretic hormone act here (antidiuretic hormone opens the water channels). Potassium-sparing diuretics work here. Aldosterone adds sodium channels and pump activity, so sodium is reabsorbed and potassium lost.
★ Order of potencyLoops (inhibit 20 to 25% of sodium chloride reabsorption) > thiazides (up to 5%) > potassium-sparing diuretics and aldosterone antagonists (2 to 3%) > carbonic anhydrase inhibitors (the “wimpiest”; the early 5% fades to 1 to 3% after 3 to 5 days). He presented the classes in descending order of potency.

Diuretics · loop diuretics

TermWhat you need to know
★ Agents and mechanismFurosemide, bumetanide, torsemide, ethacrynic acid (the one that breaks the naming pattern). They inhibit the sodium-potassium-2 chloride carrier on the luminal membrane of the thick ascending limb.
Major actionsInhibit sodium chloride reabsorption by 20 to 25%; urine output up to 4 liters a day; more potassium, calcium and magnesium excreted → hypokalemia, hypocalcemia, hypomagnesemia.
★ Works when the kidneys do notLoops remain effective when creatinine clearance is below 30 milliliters a minute. Urine flow does not mean the kidneys are working well.
★ IndicationsPulmonary edema, nephrotic syndrome, cirrhosis of the liver (ascites), hypercalcemia (an add-on to saline, which is the main treatment), heart failure, renal failure or insufficiency, hypertension (volume-driven; not good for chronic hypertension).
★ Adverse effectsVolume depletion; hypokalemia (arrhythmias); hyperglycemia; contraction alkalosis; hyperuricemia (gout); ototoxicity (the cochlea; classically hair-cell damage, though often reversible); hyponatremia (seizures); allergic reactions (rash, photosensitivity); azotemia (blood urea nitrogen rises). Loops are the most potent, so they carry the most of these.
Why the side effects happenHyperglycemia: low potassium impairs insulin release; catecholamine release; insulin resistance. Gout: volume contraction concentrates uric acid and less is excreted. Metabolic alkalosis: volume depletion plus enhanced hydrogen ion secretion (the major factor). Mild hyperlipidemia from sympathetic activity. Reflex renin, aldosterone and antidiuretic hormone rise.
VasodilationLoops also dilate vessels: they stimulate prostaglandin E2 (blocked by non-steroidal anti-inflammatory drugs), plus a direct muscle-relaxing effect of unknown mechanism.
★ InteractionsNon-steroidal anti-inflammatory drugs blunt the natriuretic and blood pressure response · aminoglycosides potentiate ototoxicity · warfarin competes for plasma protein binding · lithium clearance falls and toxicity rises · digitalis: hypokalemia plus hypomagnesemia gives arrhythmias.
FLAG: boxed warningFDA boxed warning, not on the slide: furosemide, bumetanide and ethacrynic acid carry a boxed warning for profound diuresis with water and electrolyte depletion when given in excess. Torsemide does not.

Diuretics · thiazides

TermWhat you need to know
★ Agents and mechanismChlorothiazide, hydrochlorothiazide, chlorthalidone, metolazone, indapamide. They inhibit the sodium/chloride transporter in the distal convoluted tubule (major action).
Major actionsInhibit up to 5% of filtered sodium chloride; urine output 1 to 2 liters a day; more potassium and magnesium excreted; LESS calcium excreted (more calcium reabsorbed in the proximal and distal tubules). Acutely lower the glomerular filtration rate.
★ The calcium paradoxThiazides keep calcium from being excreted, so they help patients with calcium oxalate kidney stones yet can cause a small rise in serum calcium. Less calcium in the urine means less to crystallize. Loops do the opposite.
★ HypertensionCheap, old and well tolerated. He described them as a useful second- or third-line add-on (current hypertension guidelines still list thiazides among first-line choices). Works best in elderly patients, African American patients and sodium-retentive states. Short term: lower blood volume and cardiac output; chronic: vessel relaxation, less sodium “waterlogging” of vessel walls, lower total peripheral resistance. Low-dose thiazides are preferred, with few adverse effects.
Other indicationsHypertension, renal failure, cirrhosis of the liver, congestive heart failure, renal calcium stones.
★ Adverse effectsVolume depletion with reflex sympathetic and renin-angiotensin-aldosterone activation; hypokalemia; metabolic alkalosis; hyperuricemia (gout); hyperglycemia (less insulin); hypercalcemia; hyperlipidemia (a modest rise in low-density lipoprotein); rash, photosensitivity; dizziness, headache, weakness, restlessness; sexual dysfunction; constipation. Much of the loop list, only milder; the differences are that thiazides RAISE calcium and are not ototoxic.
★★ MetolazoneThiazides lose effect at low creatinine clearance, but metolazone still works. His mnemonic: “metolazone could make a rock pee”. (FLAG, see the last topic: do not treat “thiazides do not work in kidney failure” as absolute.)
★ InteractionsNon-steroidal anti-inflammatory drugs block prostaglandins and weaken the natriuretic action. Digitalis toxicity rises with potassium loss: keep potassium above 4.0 milliequivalents per liter.

Diuretics · potassium-sparing and aldosterone antagonists

TermWhat you need to know
★ Potassium-sparing: agents and mechanismAmiloride and triamterene block luminal sodium channels in the collecting duct, inhibiting 2 to 3% of sodium chloride reabsorption and decreasing the gradient for potassium secretion. Modest increase in urine flow. Combination products with hydrochlorothiazide exist.
Potassium-sparing: useSame indications as the others but much less natriuretic and diuretic effect; most often combined with another diuretic or an antihypertensive. A loop plus a potassium-sparing drug offsets the potassium loss.
★ Potassium-sparing: adverse effectsHyperkalemia (the major difference from other diuretics); caution with angiotensin-converting enzyme inhibitors, angiotensin blockers and potassium supplements; glucose intolerance in diabetes; megaloblastic anemia (triamterene); azotemia (amiloride). Salt substitutes are usually potassium chloride, a hidden potassium source.
FLAG: boxed warningFDA boxed warning, not on the slide: amiloride and triamterene both carry a boxed warning for hyperkalemia.
Aldosterone: normal actionAldosterone binds its receptor, moves to the nucleus and drives protein synthesis: more sodium channels, more sodium-potassium pump activity, more energy production in the distal tubule.
★ Aldosterone antagonists: agents and mechanismSpironolactone, eplerenone. They bind the steroid receptor but do not move to the nucleus, so they work best when aldosterone is high. Block 2 to 3% of sodium chloride reabsorption and reduce potassium loss; modest effect on lipids, glucose and uric acid.
★ Aldosterone antagonists: indicationsPrimary aldosteronism, hypertension, heart failure, edematous conditions, cirrhosis (secondary hyperaldosteronism), nephrotic syndrome. Heart failure is the big one: advanced (class III or IV) failure; see FLAG.
★★ Aldosterone antagonists: adverse effectsHyperkalemia and mild acidosis; nausea, vomiting, gastrointestinal upset; sex-hormone effects of spironolactone (it blocks the androgen receptor; see FLAG) → gynecomastia in men; menstrual irregularities in women (the slide also lists testicular atrophy). Eplerenone has less effect on androgen receptors: switch to it if the patient complains of breast development or menstrual problems.

Diuretics · carbonic anhydrase inhibitors

TermWhat you need to know
★ Agents and mechanismAcetazolamide, dichlorphenamide, methazolamide. Inhibit carbonic anhydrase: bicarbonate absorption in the proximal tubule falls by 80 to 90%, less hydrogen ion production, less hydrogen/sodium exchange. Bicarbonate is trapped in the tubule and passed out (alkaline urine, a mild acidification of the patient).
Weak and self-limitingShort term sodium and potassium excretion rises about 5%, but after 3 to 5 days the effect shrinks to 1 to 3% because the rest of the nephron compensates. The wimpiest diuretic.
★ Other usesGlaucoma (less bicarbonate in the ciliary body: dorzolamide, brinzolamide), epilepsy (metabolic acidosis, central nervous system effects), mountain sickness (acidifies the blood so the patient breathes faster).
★ Adverse effectsMetabolic acidosis (the opposite of the contraction alkalosis of other diuretics), potassium depletion, drowsiness.

Heart failure · types, compensation, non-drug care

TermWhat you need to know
CausesIschemic heart disease and myocardial infarction (50 to 60% of cases), hypertension, idiopathic dilated cardiomyopathy; other cardiomyopathies (alcoholic, viral, hypertrophic); drug induced.
★ Systolic dysfunctionDecreased contractility (loss of muscle mass, left ventricular hypertrophy, dilated cardiomyopathies), assessed as a reduced ejection fraction (the slide says below 45%; current practice says 40% or less).
★ Diastolic dysfunctionImpaired relaxation: thicker, stiffer ventricles; ischemia impairs removal of calcium back into the sarcoplasmic reticulum; less filling means less cardiac output. Symptoms with a preserved ejection fraction.
Compensatory responseMore preload (sodium and water retention), vasoconstriction, tachycardia and more contractility (sympathetic activation), left ventricular hypertrophy. A vicious cycle that therapy has to interrupt.
Precipitants of decompensationLack of compliance (diet or medicines), uncontrolled hypertension, arrhythmias, inadequate therapy, inappropriate medicines or fluid overload; also acute anginal chest pain, pulmonary infection, emotional stress.
Non-drug therapyRestrict dietary sodium and fluid (the slide gives 1 to 3 grams of sodium and under 2 liters of fluid a day); physical activity may improve function.

Heart failure · diuretics, ACE inhibitors, beta blockers

TermWhat you need to know
★★ Diuretics in heart failureLoops are the mainstay; thiazides are not potent enough for most patients. They cut sodium and water retention and so preload, for symptomatic benefit only: no evidence they slow progression or lower mortality, and not mandatory (some patients take them as needed). Daily weights detect fluid overload.
★ Angiotensin-converting enzyme inhibitors: what they doLower preload, afterload and sympathetic activation; reduce left ventricular hypertrophy, dilation and remodeling; slow progression; lower mortality. Hemodynamics, exercise tolerance, symptoms, admissions, progression and survival all improve. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have to be mandatory in heart failure with reduced ejection fraction (a weak pumping heart; the slide does not name the type).
Angiotensin-converting enzyme inhibitor problemsRenal function impairment, hypotension, raised serum potassium, cough, angioedema. Loops lower potassium, angiotensin-converting enzyme inhibitors raise it: monitor.
★★ Beta blockers: only threeBeta blockers were classically considered contraindicated in heart failure. The ones with a mortality benefit are carvedilol, metoprolol succinate (the extended-release form) and bisoprolol; the others have not shown it.
★ Beta blockers: low and slowPatient stable before starting; in hospital preferred; very low starting doses; titrate up slowly (the slide says over 6 to 8 weeks total); monitor for worsening heart failure signs and symptoms. Heart rate and contractility fall, so a rushed start can decompensate the patient.
Beta blockers: benefit and placeBetter exercise tolerance, a higher ejection fraction, slower progression, fewer hospitalizations, less need for transplant, lower mortality. First line in class II to IV heart failure; patients should be on an angiotensin-converting enzyme inhibitor AND a beta blocker irrespective of symptoms.

Heart failure · digoxin

TermWhat you need to know
Structure and sourceLactone ring and steroid nucleus are essential for activity; the sugar molecules influence absorption, half-life and metabolism.
★ MechanismInhibits the sodium-potassium ATPase → intracellular sodium rises → calcium enters through the sodium/calcium exchanger → force of contraction rises (the older, inotropic mechanism). The newer one is neurohormonal: less sympathetic and more parasympathetic activity, baroreflex resensitized, renin-angiotensin-aldosterone system down, so the heart rate falls (more parasympathetic effect on the atrioventricular node) and cardiac output rises.
★ Narrow therapeutic indexThere is little gap between an effective and a toxic level, and it is one of the few heart failure drugs whose level is checked. Target range on the slide: 0.5 to 1 nanogram per milliliter; higher concentrations are associated with worse outcomes in heart failure. He will probably not quiz the number.
★★ Benefit: symptoms, NOT survivalBetter symptoms, exercise tolerance and quality of life; fewer hospitalizations; NO SURVIVAL BENEFIT; no evidence of slowed disease progression. So it is not mandatory like angiotensin-converting enzyme inhibitors and beta blockers.
★ Place in therapySymptomatic patients already on optimal angiotensin-converting enzyme inhibitor/beta blocker and diuretic therapy; can be used for rate control in atrial fibrillation with heart failure; considered in symptomatic systolic dysfunction. (FLAG: the slide says “first line” for the atrial fibrillation case; that is overstated.)
★ ToxicityGastrointestinal: anorexia, nausea. Visual: blurred vision, photophobia, xanthopsia, yellow-green halos around lights. Central: delirium, fatigue, confusion, dizziness, abnormal dreams. Cardiac: nodal slowing (longer PR interval, shorter QT interval, depressed ST segment), bradycardia, digoxin-induced afterdepolarization (the tracing shows premature ventricular beats and ST depression).
★★ Contraindications and risk factorsAdvanced atrioventricular block; severe bradycardia or sick sinus syndrome; premature ventricular beats and ventricular tachycardia; Wolff-Parkinson-White syndrome. Toxicity is more likely with hypokalemia, hypomagnesemia and hypercalcemia: loops and thiazides lower potassium and magnesium, so a patient on digoxin plus a diuretic needs electrolyte monitoring. (FLAG: slide 71 prints hyperkalemia; see the last topic.)
★ Antidote: digoxin immune FabAn antibody fragment made by immunizing healthy sheep with digoxin coupled to human serum albumin; its affinity for digoxin is higher than digoxin's affinity for the sodium-potassium ATPase, so it rapidly reverses toxicity. It can unmask what digoxin was treating (atrial fibrillation or heart failure decompensation).

Heart failure · other agents

TermWhat you need to know
★ Aldosterone antagonists in heart failureSpironolactone lowers mortality in advanced (class III or IV) heart failure (the slide says “grade”) by neurohormonal inhibition and slowed left ventricular remodeling. Not eligible if potassium is above 5 or serum creatinine above 2.5. Gynecomastia in men (about 10%; may respond to a lower dose); eplerenone rarely causes gynecomastia.
Milrinone and inamrinonePhosphodiesterase type 3 inhibitors (cyclic adenosine monophosphate up): direct stimulation of contraction plus balanced arterial and venous dilation → lower afterload, higher cardiac output. Approved for short-term intravenous use in acute decompensated heart failure; long-term use carries higher mortality and morbidity than placebo. Adverse: thrombocytopenia (milrinone less), ventricular arrhythmias.
★ Dobutamine and dopamineDobutamine: selective beta-1 agonist, intravenous; stimulates force of contraction more than rate; short-term use to stabilize patients. Dopamine: intravenous, acts through dopamine and beta receptors. They vasodilate much less than milrinone, so they suit a hypotensive decompensation; milrinone suits a hypertensive one.
★ IvabradineBlocks the hyperpolarization-activated cyclic nucleotide-gated channel (pacemaker current in the sinoatrial node): lowers heart rate without affecting contractility. For patients maxed out on beta blockers who are in normal sinus rhythm with a heart rate above 70; fewer hospitalizations and heart failure deaths. Adverse: atrial fibrillation risk, symptomatic bradycardia, visual impairment (phosphenes, halos, may resolve). Contraindications resemble beta blockers: hypotension, heart block, pacemaker.
★ Sacubitril-valsartanSacubitril is a neprilysin inhibitor (neprilysin normally degrades natriuretic peptide, bradykinin and other vasoactive peptides): vasodilation, natriuresis, diuresis, less myocardial growth and fibrosis. Formulated with valsartan, an angiotensin receptor blocker. Reduces cardiovascular death and hospitalization. Never with an angiotensin-converting enzyme inhibitor: 36-hour washout. Common adverse: hypotension, hyperkalemia, cough, renal insufficiency.
FLAG: sacubitril-valsartanFDA boxed warning, not on the slide: fetal toxicity. A history of angioedema is also a contraindication.
★ Sodium-glucose cotransporter 2 inhibitorsDapagliflozin, empagliflozin. For stable chronic heart failure with reduced ejection fraction: reduce mortality and hospitalizations. Originally for diabetes: the kidneys stop reabsorbing glucose. Risks: hypotension and fungal infections of the genitourinary tract (the slide says “fungal urinary tract infections”). A “necessary add-on” for heart failure patients.

Deck versus truth · learn the true version

TermWhat you need to know
FLAG: digoxin and potassiumSlide 71 lists hyperkalemia as a digoxin contraindication, and he said “hyperkalemic” once. Slides 19 and 29 (and the pharmacology) say the opposite: hypokalemia, hypomagnesemia and hypercalcemia raise toxicity risk. Learn hypokalemia.
FLAG: descending limbThe descending limb is permeable to water (the slide: “water leaves lumen”); he misspoke once. The thick ascending limb is the impermeable one.
FLAG: thiazides and calciumSlide 24 lists hypercalcemia among thiazide indications. Thiazides raise serum calcium and lower urinary calcium: they treat calcium stones, not hypercalcemia (saline hydration is the main treatment, with a loop diuretic added).
FLAG: thiazides at low clearanceSlide 28: thiazides are ineffective below a creatinine clearance of 30 to 40. Learn metolazone works at low clearance; do not memorize “thiazides never work in kidney disease” (newer trials show chlorthalidone works in advanced kidney disease).
FLAG: uric acid with thiazidesSlide 23 says thiazides increase uric acid excretion acutely; slide 26 and the clinical picture are hyperuricemia and gout. Learn hyperuricemia.
FLAG: aldosterone antagonists and classSlide 37 says heart failure “class IV”; slide 73 says “grade III or IV.” Learn advanced (class III or IV) heart failure. The slide 36 lines on a 30 to 60 minute lag and on calcium excretion are not carried here.
FLAG: spironolactone and androgen receptorsSlide 38 calls spironolactone a “partial agonist at testosterone receptors” with “weak androgenic effects” (he repeated the partial agonist wording). Spironolactone actually BLOCKS (antagonizes) the androgen receptor, which is why it causes gynecomastia and menstrual irregularities. Hirsutism is not an adverse effect of it (the slide lists it, but spironolactone is used to treat hirsutism): do not learn it as one.
FLAG: antidiuretic hormone and waterSlide 10 says water movement in the distal tubule is controlled by aldosterone. Aldosterone drives sodium and potassium handling; antidiuretic hormone controls the collecting duct water channels (slides 11, 30, 34).
FLAG: ejection fraction and weight numbersReduced ejection fraction is now 40% or less (slide 46 says below 45%). The weight gain of more than 1 pound a day (slide 52) is a teaching figure: learn daily weights, and rapid gain means fluid.
FLAG: dopamine and the kidneySlide 77 says dopamine infusions maintain renal function. Low-dose dopamine has not been shown to protect the kidneys; do not rely on that claim.
FLAG: carbonic anhydrase notesSlide 21 (thiazides have some carbonic anhydrase activity and phosphodiesterase inhibition at high doses) and slide 42 (head injury, less swelling) are not examined points: he said not to worry about the carbonic anhydrase action.
Other boxed warnings (not on the slides)FDA boxed warnings not on the slides: furosemide, bumetanide, ethacrynic acid (profound diuresis); amiloride, triamterene (hyperkalemia); sacubitril-valsartan (fetal toxicity); angiotensin-converting enzyme inhibitors (fetal toxicity); abrupt beta blocker withdrawal (metoprolol).

Antiarrhythmics · what he stressed

TermWhat you need to know
★★ Know which drug is in which classHe does not care about channel affinity, but you must recognize which drugs fit in 1A, 1B and 1C. 1A = PDQ: procainamide, disopyramide, quinidine. 1B = lidocaine. 1C = flecainide, propafenone. Class II = beta blockers; class III = amiodarone, dofetilide, sotalol; class IV = verapamil, diltiazem; others = adenosine, digoxin (plus magnesium sulfate).
★★ The indication trendDo not memorize the indication list; read the trend. Class I and class III: both supraventricular and ventricular arrhythmias (except 1B lidocaine: ventricular only). Class II, class IV and the miscellaneous agents: supraventricular (verapamil and diltiazem are to be avoided in ventricular arrhythmias).
★ Rate control versus rhythm controlHis framing (the slides do not use the words): rhythm control puts and keeps the patient in normal sinus rhythm (class I; quinidine “maintain rhythm”, dofetilide “normal rhythm in atrial fibrillation”). Rate control limits how many beats reach the ventricles (class II, class IV; digoxin “slow ventricular rate”).
Not testedChannel affinity (open > inactivated) and dissociation rate for 1A, 1B and 1C: he said he would not harp on them.
★ Torsades de pointes → magnesium sulfateTorsades de pointes is listed for quinidine (2-8%), procainamide, disopyramide, dofetilide (1-3%, marked QT prolongation) and sotalol. Its treatment: intravenous magnesium sulfate (“always magnesium sulfate”).
★ Every antiarrhythmic can cause an arrhythmiaPrinciples: identify and remove precipitating factors first (hypoxia, ischemia, electrolytes); set the goal (terminate or prevent); all antiarrhythmics may induce arrhythmias; ischemia makes the heart a “moving target”.
DosesThis site leaves milligram and gram amounts out (including the magnesium sulfate amount); doses are not tested in this course, per the earlier lectures. Half-lives, routes and percentages are kept.

Antiarrhythmics · classes and the action potential

TermWhat you need to know
Four mechanismsSodium channel blockers: decrease excitability. Potassium channel blockers: prolong the action potential. Beta receptor blockade: prolongs atrioventricular refractoriness and conduction, raises the energy needed for fibrillation. Calcium channel blockers: decrease slow-response (nodal) cell excitability.
Sodium channel statesResting (closed, no sodium in) → activated (open, sodium rushes in: phase 0) → inactivated (gate plugs the channel while the cell repolarizes) → recovery to resting. Class I drugs act on this channel.
Ischemia moves the targetIschemia may alter the resting membrane potential, so the target shifts. That is why lidocaine (1B) acts mainly on ischemic tissue and leaves normal tissue largely alone.
Reading the picturesSolid line = normal; dashed = with the drug. 1A: slower, lower phase 0, longer action potential. 1B: same upstroke, phase 3 ends sooner (shorter). 1C: markedly slower phase 0. III: same upstroke, phase 3 delayed (longer). II and IV: flatter phase 4 in pacemaker cells, so the next beat comes later.
Memory aid: the nightclubA story, not a fact source. Sinoatrial node = DJ; atrioventricular node = the door; ventricles = the main room. Rate control works the door: class II beta blockers are the bouncer, class IV a second bouncer using calcium, digoxin turns up the calming (parasympathetic) music. Door staff cannot stop a fight inside the main room (II and IV: supraventricular only). Rhythm control works on the dancers: class I slows the first step (phase 0), class III makes them rest longer (phase 3). Rest too long and the floor twists (torsades), untwisted by magnesium. Adenosine flips the power off for 2 to 3 seconds.

Class IA · quinidine, procainamide, disopyramide (PDQ)

TermWhat you need to know
Class IA actionsSlow phase 0, slow conduction, prolong the action potential. Indications (class): supraventricular tachycardia, ventricular tachycardia, prevention of ventricular fibrillation and premature ventricular contractions.
Quinidine: what it is and doesD-isomer of quinine. Slows conduction, prolongs the refractory period, slows phase 0, raises the excitability threshold, decreases automaticity. Indirect: anticholinergic; alpha blocker at higher doses (hence hypotension).
Quinidine: uses and interactionMaintain rhythm with atrial flutter or fibrillation; control ventricular tachycardia; conversion of flutter and fibrillation (very limited use). CYP2D6 (cytochrome P450 2D6) inhibitor (codeine, morphine).
★ Quinidine toxicityNausea, vomiting, diarrhea (30-50%); ventricular and atrial arrhythmias; hypotension; thrombocytopenia (may be fatal); cinchonism = tinnitus, dizziness, blurred vision; quinidine sudden death; torsades de pointes (2-8%); immunological reactions.
Procainamide: kineticsAmide derivative of procaine. Short duration (3-4 hours) → slow-release preparation. Less anticholinergic than quinidine, no alpha block. Active acetylated metabolite NAPA (N-acetylprocainamide) has class III activity; fast acetylators may make more of it.
★ Procainamide adverse effectsLupus-like syndrome (25-50%, more often in slow acetylators); hypotension; slowed conduction; nausea; torsades de pointes; bone marrow suppression (0.2%). Intravenous: better tolerated than quinidine. Oral: poorly tolerated long term.
DisopyramideLike quinidine, but more anticholinergic and negative inotropic. For ventricular tachycardia and supraventricular arrhythmias (flutter, fibrillation). Toxicity: hypotension, antimuscarinic effects, conduction disturbances, congestive heart failure (lower contractility), torsades. Contraindicated: heart block, hypersensitivity, glaucoma.
Telling PDQ apartCinchonism, diarrhea, fatal thrombocytopenia, cytochrome P450 2D6 inhibition → quinidine. Lupus-like syndrome, acetylators, class III metabolite → procainamide. Most anticholinergic, glaucoma, heart block, heart failure → disopyramide.

Class IB · lidocaine

TermWhat you need to know
★ Class IB actionsShorten phase 3 (shorter action potential); decrease ectopic foci automaticity. Higher affinity in ischemic tissue, little effect in normal tissue. Indications (class): ventricular only.
Lidocaine indicationsVentricular tachycardia and premature beats; ventricular fibrillation; acute myocardial infarction; Wolff-Parkinson-White is also listed (see the guidelines topic).
★ Route and reachIntravenous only: extensive first-pass metabolism. Most effective on sodium channels in ischemic tissue. Not effective against atrial arrhythmias.
★ Lidocaine toxicityCentral nervous system: drowsiness, confusion, restlessness, muscle twitches, seizures. Nystagmus = early sign of toxicity. Hypersensitivity; increases atrioventricular conduction. Contraindications: seizures, age.

Class IC · flecainide, propafenone

TermWhat you need to know
Class IC actionsSlow phase 0 (the most of class I), slow conduction, prolong the refractory period, affect the normal heart. Indications (class): life-threatening ventricular tachycardia or fibrillation, refractory supraventricular tachycardia.
Flecainide: actions and kineticsBlocks sodium and potassium channels in the ventricles; slows sodium channel recovery; prolongs the PR, QRS and QT intervals; prevents premature ventricular contractions. Long half-life (14 hours); oral or intravenous.
★ Flecainide: who gets itLife-threatening sustained ventricular arrhythmias; supraventricular arrhythmias. Only in patients WITHOUT significant structural heart damage; increased mortality after myocardial infarction is on its toxicity list.
Flecainide toxicityBlurred vision, tremor; ventricular tachycardia resistant to treatment; bronchospasm; seizures; thrombocytopenia; increased mortality after myocardial infarction. Boxed warning (not on the slide): the Cardiac Arrhythmia Suppression Trial mortality.
PropafenoneSame mechanism as flecainide + beta-blocking activity. Toxicity: proarrhythmic; dizziness, blurred vision, bradycardia; bronchospasm (beta blockade); agranulocytosis, anemia, thrombocytopenia; worsens heart failure.

Class II · beta blockers

TermWhat you need to know
★ Class II actionsSlow conduction, decrease automaticity, prolong atrioventricular conduction, decrease phase 4 depolarization (pacemaker cells reach threshold later). His image: the beta blocker is the bouncer at the door (rate control).
PropranololNonselective. Reduces phase 4 activation, slows atrioventricular conduction, negative inotropic and chronotropic, suppresses premature ventricular beats, membrane stabilizing. Uses: supraventricular arrhythmias, ventricular ectopic beats, myocardial infarction.
★ Propranolol toxicityHeart failure, heart block, hypotension, bronchospasm (nonselective: asthma), digitalis toxicity. Hyperglycemia is also listed (see the guidelines topic).
★ Metoprolol, acebutolol, esmololBeta-1 selective, similar to propranolol, less bronchospasm (choose these in asthma). Still: congestive heart failure; sedation and fatigue. Esmolol = intravenous, short-acting.

Class III · amiodarone, dofetilide, sotalol

TermWhat you need to know
Class III actionsReduce potassium efflux, prolong phase 3 repolarization, prolong the refractory period and the action potential. Indications (class): refractory ventricular tachycardia, atrial fibrillation, flutter, supraventricular tachycardia.
★ Amiodarone: what it isOral and intravenous; analog of thyroid hormone. Half-life about 40 days (26-107): slow onset, slow elimination, so loading doses. Blocks potassium, inactivated sodium and calcium channels and alpha and beta receptors; decreases automaticity and conduction; prolongs refractory periods.
Amiodarone: usesRecurrent ventricular tachycardia or fibrillation resistant to other drugs; maintain normal rate in atrial fibrillation. Intravenous: terminates acute ventricular tachycardia or fibrillation, replacing lidocaine in myocardial infarction.
★ Amiodarone toxicityHypotension; pneumonitis, pulmonary fibrosis (potentially fatal); neurotoxicity, neuropathy, muscle weakness, ataxia; blue-gray skin, photosensitivity; corneal deposits; thyroid abnormalities (hyper or hypo); hepatic dysfunction. Boxed warning (not on the slide): pulmonary and hepatic toxicity.
Amiodarone interactionsIncreases digoxin, warfarin, flecainide, phenytoin and procainamide.
★ DofetilidePotent pure potassium channel blocker. For normal rhythm in atrial fibrillation. Limited availability to those with special training. Torsades de pointes (1-3%), marked QT prolongation. Mainly eliminated unchanged by the kidneys. Boxed warning (not on the slide): start in a monitored facility.
★ Sotalol = class II + class IIIBeta-blocking activity plus potassium channel block; decreases phase 4 depolarization; longer action potential; slower atrioventricular node conduction. For atrial flutter and fibrillation, ventricular tachyarrhythmia. Toxicity: torsades de pointes, bronchospasm, beta-blocking effects.

Class IV · verapamil, diltiazem

TermWhat you need to know
Class IV actionsBlock the L-type calcium channel; decrease automaticity; slow atrioventricular node conduction; negative inotropic. Block activated and inactivated channels; most effective in the most active tissue; suppress the sinoatrial node.
★ Verapamil and diltiazem: use and avoidFor paroxysmal supraventricular tachycardia and atrial fibrillation. Toxicity: hypotension, edema. Hepatic metabolism: caution in liver damage. Avoid in ventricular arrhythmias, sick sinus syndrome, depressed cardiac function.

Miscellaneous · adenosine, digoxin, magnesium sulfate

TermWhat you need to know
★ Adenosine: actionActivates potassium channels in the atria and blocks calcium channels → hyperpolarizes cells. Slows conduction velocity: may stop the heart for 2-3 seconds; decreases automaticity; prolongs the refractory period. Half-life about 10 seconds. His image: turn it off and back on.
Adenosine: use and toxicityParoxysmal supraventricular tachycardia (Wolff-Parkinson-White also listed). Toxicity: flushing (20%), shortness of breath, burning in the chest.
Digoxin: actionSodium-potassium ATPase inhibition; slows atrioventricular conduction; inhibits calcium channels in the atrioventricular node; indirectly raises parasympathetic tone, lowers sympathetic; can induce heart block.
★ Digoxin: use, toxicity, avoidSlow the ventricular rate; induce heart block in atrial flutter and fibrillation. Toxicity: nausea, vomiting, diarrhea, anorexia; confusion, delirium, headache, seizures, visual disturbances. Avoid calcium channel blockers and beta blockers with it (additive slowing and heart block).
★ Magnesium sulfateIndication: torsades de pointes, intravenous (the treatment of choice he named). Toxicity: bradycardia, flushing, headache, respiratory paralysis.

Antiarrhythmics · which drug causes it

TermWhat you need to know
More than one class in one drugAmiodarone: potassium, inactivated sodium and calcium channels plus alpha and beta receptors. Sotalol: beta block + potassium block. Propafenone: flecainide’s sodium block + beta block. Procainamide: its metabolite NAPA (N-acetylprocainamide) has class III activity. Quinidine: anticholinergic + alpha block. Flecainide: sodium + potassium channels.
BronchospasmPropranolol (nonselective), sotalol and propafenone (beta-blocking activity), and flecainide. Metoprolol and acebutolol: less bronchospasm.
Blood countsQuinidine: thrombocytopenia (may be fatal). Procainamide: bone marrow suppression (0.2%). Flecainide: thrombocytopenia. Propafenone: agranulocytosis, anemia, thrombocytopenia.
Weaker pump, heart failureDisopyramide (negative inotropic, congestive heart failure), propafenone (worsens heart failure), propranolol and metoprolol (heart failure), verapamil and diltiazem (negative inotropic; avoid with depressed cardiac function).
Heart blockDigoxin can induce heart block (the aim in atrial flutter and fibrillation). Propranolol lists heart block. Disopyramide is contraindicated in heart block.
Eyes and brainBlurred vision: quinidine (cinchonism), flecainide, propafenone. Nystagmus: lidocaine (early toxicity). Corneal deposits: amiodarone. Visual disturbances: digoxin. Glaucoma contraindicates disopyramide. Seizures: lidocaine, flecainide, digoxin.

Antiarrhythmics · slide versus guideline and recording

TermWhat you need to know
Tested from the slidesThese rows say where practice or the recording differs. The slide wording is what you are tested on; none of these points is asked as a question here.
Current guidelines differ: lidocaineSlide 17 lists Wolff-Parkinson-White as a lidocaine indication. Lidocaine is not a recommended treatment for Wolff-Parkinson-White syndrome.
Current guidelines differ: adenosineSlide 42 lists Wolff-Parkinson-White. Adenosine can end the reentrant tachycardia of Wolff-Parkinson-White, but it is avoided when the syndrome presents as pre-excited atrial fibrillation.
Current guidelines differ: amiodaroneSlide 31: intravenous amiodarone has replaced lidocaine for acute ventricular tachycardia or fibrillation. Resuscitation guidance lists amiodarone or lidocaine as options for shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.
Current guidelines differ: digoxin combinationsSlide 44: avoid calcium channel blockers and beta blockers with digoxin. In practice digoxin is often combined with a beta blocker or a nondihydropyridine calcium channel blocker for rate control in atrial fibrillation, with the heart rate watched for excessive slowing.
Recording vs slide: propranolol and glucoseSlide 28 lists hyperglycemia. He read the glucose line and added that beta blockers can mask the warning signs of hypoglycemia (low blood sugar); he did not call the slide wrong. The two transcripts of the recording disagree on whether his first word was hyper- or hypoglycemia, so this point is not asked.
Recording vs slide: seizuresHe said seizures are a lidocaine feature not really seen with other class I drugs, but slide 23 also lists seizures for flecainide. Do not treat seizures as unique to one drug; nystagmus is lidocaine's alone.
Recording vs slide: beta blockers and ventricular beatsHis trend: beta blockers do not work for ventricular arrhythmias. Slides 26 and 27 still list premature ventricular beats and ventricular ectopic beats for propranolol (membrane stabilizing; he called that use “out in the weeds”).
Boxed warnings (not on the slides)Food and Drug Administration boxed warnings not on the slides: flecainide (increased mortality, from the Cardiac Arrhythmia Suppression Trial); amiodarone (pulmonary and hepatic toxicity); dofetilide (start in hospital with monitoring, which he also described).

Pulmonary · what he stressed

TermWhat you need to know
★★ The broad nosocomial regimen (“there will be a question like this”)Name each drug's class, then check: ONE antipseudomonal beta-lactam (cefepime or ceftazidime; imipenem/cilastatin or meropenem; piperacillin/tazobactam) + ONE antipseudomonal fluoroquinolone or aminoglycoside (levofloxacin, ciprofloxacin; gentamicin, tobramycin, amikacin) + vancomycin or linezolid. Fails: two beta-lactams (same mechanism); two gram-positive drugs with one gram-negative; ertapenem (limited Pseudomonas activity) or ceftriaxone in the beta-lactam slot.
★★ Quick relief or controller, for every asthma drugQuick relief: short-acting beta-2 agonists, anticholinergics, systemic corticosteroids. Long-term controllers: long-acting beta-2 agonists, inhaled corticosteroids, leukotriene modifiers, mast cell stabilizers, anti-immunoglobulin E antibody, theophylline. Burning through the rescue inhaler = poor control.
★★ Stepwise asthma therapy: what to start, what comes nextPreferred controllers step up: daily low-dose inhaled corticosteroid → low-dose inhaled corticosteroid + long-acting beta-2 agonist → medium dose → high dose + referral for phenotypic assessment (add-on tiotropium or a biologic). Albuterol is a reliever, not a controller; theophylline and biologics are not first line. Either reliever (as-needed inhaled corticosteroid-formoterol or a short-acting beta-2 agonist) is acceptable.
★ Never a long-acting beta-2 agonist alone in asthmaFormoterol and salmeterol are always paired with an inhaled corticosteroid for asthma (Symbicort, Dulera, Advair). He noted chronic obstructive pulmonary disease is different.
★ Inhaled corticosteroids: the mainstayThe gold-standard controller; up to 8 weeks for maximal effect, so keep taking it; rinse the mouth (thrush).
★ Rifampin is an inducerNot an inhibitor: an inducer. Anticoagulants, contraceptives and digoxin fall (counsel on contraception). Then liver injury and orange secretions.
★ Cultures before antibiotics; linezolid without renal adjustmentHospitalized pneumonia: blood and sputum cultures before the first antibiotic. Every hospital pneumonia antibiotic needs renal adjustment except linezolid.
★ Anaphylaxis: epinephrine first when airway or circulation failAirway or cardiovascular compromise: epinephrine right away (intramuscular or subcutaneous; intravenous only if coding). It acts at once; corticosteroids take hours.
Not testedThe pathogen lists by setting (slide 12: learn the trend), the second-line tuberculosis list (slide 46), the vancomycin trough number (slide 29), classifying a patient's asthma severity (slide 65), which interleukin each biologic targets (slide 81: know interleukin against immunoglobulin E), and doses.

Pulmonary · acute bronchitis and community-acquired pneumonia

TermWhat you need to know
Acute bronchitis: what it isInflammation of one or more bronchi, usually infectious; spares the bronchioles and alveoli. Acute: all ages. Chronic: mainly patients with chronic obstructive pulmonary disease. Mostly viral (rhinovirus, coronavirus, influenza, adenovirus); occasionally Mycoplasma, Chlamydia pneumoniae, Bordetella pertussis.
Acute bronchitis: treatmentSelf-limited: supportive care (analgesics, antipyretics, antitussives, fluids). Possibly avoid antihistamines and sympathomimetics: they dehydrate secretions and may prolong symptoms. No routine antibiotics. Symptoms over 5 days: think bacterial; doxycycline preferred if Mycoplasma is documented (macrolide resistance); macrolides; a respiratory fluoroquinolone only after recent antibiotic exposure.
Community-acquired pneumonia: route and diagnosisMicrobes arrive by aspiration from the oropharynx (elderly), inhaled aerosols, the bloodstream or direct spread (trauma). Outpatients: empiric antibiotics, no routine tests. Hospitalized: blood and sputum cultures before antibiotics. Sputum Gram stain is controversial (contaminated; pathogen often not found).
Pathogens by settingOutpatient: S. pneumoniae, Mycoplasma, H. influenzae, Moraxella, viruses. Ward: adds Chlamydia pneumoniae, Legionella, aspiration. Intensive care unit: S. pneumoniae, Staphylococcus aureus, Legionella, gram-negative bacilli, H. influenzae.
Risk for resistant pneumococcusAge over 65; a beta-lactam in the past 3 months; alcoholism; immunosuppression; comorbidities (diabetes, renal insufficiency, heart failure, coronary disease, malignancy); a child in day care.
Outpatient regimenNo resistance risk: macrolide first line (azithromycin, clarithromycin); doxycycline or minocycline second line. Resistance risk: beta-lactam + macrolide (amoxicillin with or without clavulanic acid; cefuroxime, cefpodoxime) or a respiratory fluoroquinolone (levofloxacin, moxifloxacin), good for beta-lactam allergy.
Inpatient regimenWard: intravenous beta-lactam (cefotaxime, ceftriaxone, high-dose ampicillin) plus a macrolide, or doxycycline, or a respiratory fluoroquinolone (beta-lactam allergy). Intensive care unit: the same, all intravenous; consider methicillin-resistant S. aureus coverage.

Pulmonary · nosocomial pneumonia

TermWhat you need to know
DefinitionLung infection not present on admission, starting more than 48 hours after. Hospital-acquired, ventilator-associated and health-care associated. Second most common hospital infection, after urinary tract infection. Worse in the elderly and ventilated.
Health-care associated criteriaHospitalized more than 2 days in the past 90 days; nursing home or long-term care; recent intravenous antibiotics; chemotherapy; wound care in the past 30 days; hemodialysis.
Risk factorsUnmodifiable: age over 70, chronic lung disease, depressed consciousness, large-volume aspiration, winter admission. Modifiable: mechanical ventilation, nasogastric tube, intracranial pressure monitor, histamine H2 blocker or antacid, prior antibiotics, reintubation.
PathogensGram-negative: Pseudomonas aeruginosa most common (also E. coli, Klebsiella, Acinetobacter, Enterobacter, Serratia). Gram-positive: methicillin-resistant S. aureus most common, S. pneumoniae. Fungi: Candida, Aspergillus.
★ Treat now, treat wide, then narrowStart as soon as possible; do not wait for the culture. Broad spectrum; must cover methicillin-resistant S. aureus and Pseudomonas when multidrug-resistant pathogens are possible. Streamline once cultures and sensitivities return.
Limited or broadLate onset (5 days or more) or multidrug-resistance risk factors (prior antibiotics, colonization, hospitalization or chronic care, immunosuppression) → broad spectrum; neither → limited spectrum.
Limited spectrum (no multidrug-resistance risk)One drug: ceftriaxone, or levofloxacin or moxifloxacin (choose these if worried about atypicals), or ampicillin/sulbactam, or ertapenem (narrow-spectrum carbapenem).
Broad spectrum (multidrug-resistance risk)Antipseudomonal beta-lactam (cephalosporin, carbapenem or penicillin/beta-lactamase inhibitor) plus an antipseudomonal fluoroquinolone (levofloxacin, ciprofloxacin) or an aminoglycoside, plus vancomycin or linezolid.
AfterwardScale back as cultures return; switch to oral when possible (cheaper). Failure = wrong therapy (resistance, inadequate drug), wrong diagnosis (pulmonary embolus, neoplasm) or complications (C. difficile colitis, empyema, lung abscess).

Pulmonary · the hospital pneumonia antibiotics

TermWhat you need to know
Renal adjustment: everyone but linezolidAntipseudomonal cephalosporins, carbapenems, penicillins and fluoroquinolones, the aminoglycosides and vancomycin all need renal adjustment; linezolid needs none.
CephalosporinsCefepime (Maxipime) = fourth-generation, antipseudomonal. Ceftazidime (Fortaz): rarely used, resistance develops rapidly (see the guideline row).
Carbapenems and seizuresImipenem/cilastatin (Primaxin): caution with a seizure history. Meropenem (Merrem): less seizure risk. Ertapenem: limited activity against Pseudomonas.
PenicillinsPiperacillin/tazobactam (Zosyn). Ticarcillin/clavulanate (Timentin): not used often (gram-negative resistance).
FluoroquinolonesCiprofloxacin (Cipro), levofloxacin (Levaquin): good against atypicals (Mycoplasma, Chlamydia, Legionella); good lung penetration; rising gram-negative resistance, so use judiciously.
★ AminoglycosidesGentamicin, tobramycin, amikacin. Extended-interval (once-daily) dosing because of poor lung penetration (bigger doses, higher concentrations). Adjust to levels and renal function. Ototoxicity, nephrotoxicity.
★ VancomycinEmpiric methicillin-resistant S. aureus coverage. Trough before the third or fourth dose (steady state); the number itself is not to memorize. Renal adjustment; ototoxicity; nephrotoxic with other nephrotoxins.
LinezolidLinezolid (Zyvox): great methicillin-resistant S. aureus coverage, intravenous and oral, good lung penetration, expensive, no renal adjustment.

Pulmonary · tuberculosis drugs

TermWhat you need to know
The organismAcid-fast bacilli with a waxy mycolic acid coat; very slow growing and can lie dormant, so drugs that act on cell division work less well.
★ The regimen2 months of isoniazid, rifampin, ethambutol and pyrazinamide, then 4 months of isoniazid and rifampin. Pulmonary: 6 to 9 months. Never a single agent in active disease (resistance).
IsoniazidInhibits mycolic acid (waxy coat); bacteriostatic for latent, bactericidal for dividing bacteria; activated by bacterial catalase-peroxidase (mutation = resistance); fast and slow acetylators; enters the brain. Alone for prophylaxis, combined for active disease.
★ Isoniazid adverse effectsPeripheral neuritis from pyridoxine deficiency: give pyridoxine (B6). Hepatitis, worse with alcohol and age. Lupus-like syndrome. Brain: seizures, euphoria, psychosis, memory loss.
RifampinInhibits DNA-dependent RNA polymerase (not the human enzyme). Never alone (rapid tolerance). Uses: tuberculosis, meningococcal prophylaxis, endocarditis.
★ Rifampin adverse effectsInduces cytochrome P450 (CYP1A2, 2C9, 3A4): anticoagulants, contraceptives, digoxin, ketoconazole, theophylline fall. Orange tears, sweat and urine. Hepatitis, jaundice; flu-like syndrome; gastrointestinal upset.
★ EthambutolBacteriostatic; weakens the cell wall so the other drugs get in. 75 percent excreted unchanged: adjust in renal disease. Red-green color loss and decreased visual acuity. Raises uric acid.
★ PyrazinamideConverted to pyrazinoic acid, lowers the pH, enters macrophages; shortens the course. First 2 months only (liver). Hepatitis: monitor liver enzymes. Hyperuricemia in everyone. Avoid in pregnancy.
Second-line agents (not tested)Not tested (“I would not memorize this list”; know the big four). For reference: Streptomycin: hearing and balance. Aminosalicylic acid: gastrointestinal. Cycloserine: psychosis, seizures. Also rifabutin, macrolides, quinolones, clofazimine (leprosy), linezolid.

Pulmonary · anaphylaxis

TermWhat you need to know
What it isA severe, systemic allergic reaction: skin, airway, vessels, gut. Can end in airway obstruction, cardiovascular collapse and death.
★ EpinephrineAlpha: vasoconstriction, less vascular leak. Beta: bronchial smooth muscle relaxation. Relieves itching, hives, angioedema. Intramuscular is preferred unless the patient is coding (then intravenous). Adverse effects: anxiety, hypertension, tachycardia, nausea and vomiting, sweating; overdose: cerebral hemorrhage, myocardial infarction, pulmonary edema.
FluidsIntravenous crystalloid (0.9 percent saline) for profound vasodilation and hypotension; severe cases need far more. (Volumes are not tested.)
Histamine blockersHistamine H1 (diphenhydramine, hydroxyzine): rash, itching, hives. Histamine H2 (famotidine): the systemic vasodilation and gastrointestinal (acid) effects.
Albuterol and steroidsAlbuterol (beta-2 agonist) relaxes bronchial smooth muscle; anxiousness, tremor, tachycardia. Corticosteroids (methylprednisolone intramuscular or intravenous, prednisone) block mediator production but take several hours.

Asthma · the disease and the three approaches

TermWhat you need to know
AsthmaWidespread, reversible bronchial narrowing; eosinophilic mucosal inflammation; marked bronchial hyperresponsiveness; thickened mucosa. Dyspnea, chest tightness, wheeze, cough.
Mast cell timingAllergen + immunoglobulin E: immediate histamine, proteases, heparin; minutes: prostaglandins, leukotrienes, platelet-activating factor; hours: interleukins. Early and late reactions.
★ TriggersMost attacks are triggered by a viral respiratory infection, not by allergens. Also distilled water, exercise, cold air, rapid breathing. Methacholine challenge: the fall in FEV1 (forced expiratory volume in 1 second).
Neural pathwaysMediators also fire afferent vagal receptors (reflex bronchoconstriction) and release tachykinins (substance P), so drugs with different mechanisms all help.
★ Three approaches1. Reverse bronchospasm: beta-2 agonists, ipratropium, theophylline. 2. Remove trigger or antigen: cromolyn, nedocromil. 3. Control inflammation: steroids, lipoxygenase inhibitors.
★ Quick relief versus controllerQuick relief: short-acting beta-2 agonists, anticholinergics, systemic corticosteroids. Controllers: long-acting beta-2 agonists, inhaled corticosteroids, leukotriene modifiers, mast cell stabilizers, anti-immunoglobulin E antibody, theophylline.
Severity at a glanceIntermittent: symptoms and rescue use 2 days a week or fewer, night waking 2 a month or fewer, FEV1 over 80 percent. Severe persistent: symptoms all day, rescue several times a day, FEV1 under 60 percent.
GoalsLong term: lower bronchial responsiveness with anti-inflammatories (inhaled corticosteroids). Acute: avoid triggers and treat bronchospasm with short-acting beta-2 agonists.

Asthma · bronchodilators

TermWhat you need to know
★ Beta-2 agonistsRaise cyclic adenosine monophosphate (which inhibits myosin light chain kinase) and relax airway muscle. Short-acting: rapid, 4 to 6 hours (albuterol: ProAir, Ventolin; levalbuterol: Xopenex). Long-acting: 12 hours or more (formoterol: Foradil; salmeterol: Serevent), never alone for asthma.
Beta-2 agonist adverse effectsTachycardia, tremor, hypotension, headache, dizziness, insomnia, hyperglycemia.
★ TheophyllineNonspecific phosphodiesterase inhibitor (phosphodiesterase 4 and 5) + adenosine A2B receptor antagonist + anti-inflammatory. Narrow therapeutic index; less effective and less tolerated than long-acting bronchodilators; limited use, used in chronic obstructive pulmonary disease. Intravenous form: aminophylline.
★ Theophylline toxicityArrhythmias, convulsions, headache, nausea, insomnia, heartburn; stimulates gastric acid; diuretic. Monitor plasma levels: nausea, vomiting and cardiac effects first, then seizures and arrhythmias.
AnticholinergicsBlock acetylcholine at muscarinic receptors → bronchodilation. Ipratropium (Atrovent): short-acting, up to 8 hours. Tiotropium (Spiriva): long-acting, 24 hours or more.
Anticholinergic effectsBlind as a bat (blurred vision, dilated pupils); mad as a hatter (delirium, hallucinations); red as a beet (flushing); hot as Hades (fever); dry as a bone (dry mouth and eyes); constipation, urinary retention; tachycardia.

Asthma · controllers

TermWhat you need to know
★ Inhaled corticosteroidsBeclomethasone (QVAR), budesonide (Pulmicort), flunisolide (Aerobid), fluticasone (Flovent), mometasone (Asmanex), triamcinolone (Azmacort). Inhibit the inflammatory cascade; up to 8 weeks for full effect. Thrush; growth suppression in children (high dose); immune suppression.
Combination inhalersSymbicort = formoterol/budesonide. Dulera = formoterol/mometasone. Advair = salmeterol/fluticasone.
★ MontelukastOral leukotriene D4 antagonist at the cysteinyl leukotriene 1 receptor (Singulair); that receptor drives inflammation, bronchoconstriction, mucus. Effective in aspirin-induced asthma.
Cromolyn and nedocromilStabilize mast cells (limited use). Must be taken before the antigen exposure; up to 4 weeks; taken regularly. Inhaled. Mechanism unknown (calcium?).
★ OmalizumabAnti-immunoglobulin E monoclonal antibody (Xolair), subcutaneous every 2 to 4 weeks. Binds circulating immunoglobulin E, fewer mast cell receptors, no degranulation. Anaphylaxis, gastrointestinal upset, neutralizing antibodies, secondary malignancies; urticaria, injection site pain, bruising.
Other biologicsFor the eosinophilic phenotype. Anti-interleukin-5: mepolizumab (Nucala), benralizumab (Fasenra), reslizumab (Cinqair), intravenous. Anti-interleukin-4: dupilumab (Dupixent). Side effects like omalizumab's.
★ Systemic corticosteroidsMost potent, limited by side effects: for exacerbations. Prednisone (tablet), prednisolone (liquid), methylprednisolone and dexamethasone (oral or parenteral). Adrenal suppression, growth suppression, thin skin, hypertension, hyperglycemia, mood change, steroid myopathy, immunosuppression.

Asthma · steps, devices and status asthmaticus

TermWhat you need to know
Stepwise therapyAdjust up and down. Preferred controller: as-needed low-dose inhaled corticosteroid-formoterol (step 1) up to high-dose inhaled corticosteroid plus long-acting beta-2 agonist with phenotype referral (step 5). Preferred reliever: as-needed low-dose inhaled corticosteroid-formoterol; other reliever: as-needed short-acting beta-2 agonist.
★ NebulizerCompressor makes a mist; passive inhalation: children and elderly who cannot use a metered dose inhaler. Bigger dose, more side effects. Clean it (microbial growth).
Dry powder inhalerPowder; the patient's own inspiratory force draws it out, so not for poor inspiratory capacity.
Metered dose inhaler and spacersLiquid with a propellant; needs the most coordination; a spacer helps poor coordination. Spacer = open tube; valve holding chamber = one-way valve, no exhaling into it. Both keep the large particles back.
★ TechniqueCap off, shake (prime). Breathe out fully. Breathe in slowly as you press (with a holding chamber: press, then breathe within 5 seconds). Hold 10 seconds. Rescue inhaler: 15 to 30 seconds between puffs.
★ Albuterol overuseAlbuterol is short-term relief, used sparingly; excessive use means poor control and the long-term therapy needs adjusting. Controllers daily.
Status asthmaticusAn exacerbation unresponsive to the first bronchodilator treatment. Continuous nebulized albuterol; steroids (intravenous preferred); magnesium; ketamine if intubated (NMDA, N-methyl-D-aspartate, antagonist; releases catecholamines; emergence phenomenon, hypertension, tachycardia, vomiting).

Chronic obstructive pulmonary disease · drugs, smoking cessation, vaccines

TermWhat you need to know
The diseaseChronic airway and parenchymal inflammation, generally not fully reversible; FEV1 (forced expiratory volume in 1 second) falls faster than normal, and symptoms appear only after a big fall.
★ Groups A to DAll: stop smoking, yearly influenza and pneumococcal vaccines, activity, check inhaler technique, oxygen if chronically hypoxemic, rehabilitation. A: short-acting bronchodilator as needed. B: long-acting muscarinic antagonist or long-acting beta-2 agonist. C: long-acting muscarinic antagonist. D: long-acting muscarinic antagonist, or both long-acting classes if very breathless; inhaled corticosteroid plus long-acting beta-2 agonist if asthma overlaps.
★ SmokingCigarette smoke causes most cases; quitting returns the decline in lung function to the normal age-related rate. Combine medication with counseling; more counseling, more success.
★ Bupropion SR (Zyban)Inhibits norepinephrine and dopamine uptake (mimics nicotine's effects). Avoid with seizure disorders and monoamine oxidase inhibitors; caution with tricyclic antidepressants and venlafaxine.
Nicotine replacementPatch, gum (polacrilex), spray, inhaler. Less craving and withdrawal; 6 to 12 weeks; patch and gum over the counter; caution in cardiovascular disease (tachyarrhythmias, hypertension).
★ Varenicline (Chantix)Partial nicotine receptor agonist. Start one week before the quit date, 12 weeks. Nausea, sleep disturbance, headache. Black box warning: neuropsychiatric events (depression, suicidal ideation).
VaccinesInfluenza pneumonia is a major threat: annual influenza vaccine highly recommended, plus the pneumococcal vaccine.

Pulmonary · which drug causes it

TermWhat you need to know
SeizuresImipenem (caution with a seizure history; meropenem less), isoniazid, cycloserine, theophylline (convulsions); bupropion is avoided in seizure disorders.
LiverIsoniazid (alcohol, age), rifampin (jaundice, hepatitis), pyrazinamide (15 percent; monitor enzymes; first 2 months only).
Uric acidEthambutol raises it; pyrazinamide makes everyone hyperuricemic.
Ears, eyes, nervesOtotoxicity: aminoglycosides, vancomycin, streptomycin. Red-green loss: ethambutol. Peripheral neuritis: isoniazid. Blurred vision, dilated pupils: anticholinergics.
KidneysNephrotoxicity: aminoglycosides; vancomycin with other nephrotoxins. Ethambutol is mostly excreted unchanged.
Heart rate and pressureTachycardia: epinephrine, albuterol and the beta-2 agonists, anticholinergics, ketamine, nicotine replacement (tachyarrhythmias). Arrhythmias: theophylline.
Mouth and growthThrush and growth suppression in children: inhaled corticosteroids; growth suppression also with systemic corticosteroids.
Anaphylaxis from the treatmentOmalizumab (and the other asthma biologics, with a similar profile).
Orange, lupus, fluOrange secretions and a flu-like syndrome: rifampin. Lupus-like syndrome: isoniazid.
MindPsychosis: isoniazid, cycloserine. Emergence phenomenon: ketamine. Neuropsychiatric black box warning: varenicline. Delirium, hallucinations: anticholinergics.

Pulmonary · slide versus guideline

TermWhat you need to know
Tested from the slidesThese rows say where current practice or the slides themselves differ. The slide wording is what you are tested on; the points marked “not asked” are not asked as questions here.
Current guidelines differ: outpatient pneumoniaSlide 14: macrolide first line. The 2019 guideline prefers amoxicillin or doxycycline for a healthy outpatient and a macrolide alone only where pneumococcal resistance is low.
Current guidelines differ: health-care associated pneumoniaSlide 17 defines it; the 2016 hospital pneumonia guideline dropped the category. Durations: slide 31 gives 7 to 8 days (10 to 14 for Pseudomonas and others); the guideline gives about 7 for most (not asked).
Current guidelines differ: ceftazidime and vancomycinCeftazidime is still an option for hospital pneumonia (slide 24 says not recommended; Dr. Wood affirmed it aloud, so it is asked once). Vancomycin is now dosed to an area-under-the-curve target; the trough number on slide 29 is not asked.
Slides wrong: rifampin spectrumSlide 40 lists Neisseria and Legionella as gram-positive; both are gram-negative. Not asked.
Current guidelines differ: tuberculosisMost HIV (human immunodeficiency virus) co-infection now gets the standard 6 months; most tuberculosis outside the lungs 6 to 12 months; drug-resistant regimens are shorter than 18 to 24 months (not asked). The World Health Organization allows pyrazinamide in pregnancy (slide 45 says avoid; that is keyed).
Slides wrong: theophylline eliminationSlide 85 says renally eliminated; theophylline is mainly metabolized by the liver (rifampin's enzyme induction lowers it, slide 42). The units differ between slides 84 and 85 (mcg/ml against mg/ml). Neither the route nor a level is asked.
Slides disagree: tiotropiumSlide 86: tiotropium “COPD only” (chronic obstructive pulmonary disease). Slide 90 lists add-on tiotropium at asthma steps 4 and 5; aloud he said “mostly for COPD only, occasionally for more difficult to control asthma.” Not asked.
Current labeling differs: montelukastSlide 75: side effects minimal (he repeated it aloud). Since 2020 montelukast carries a boxed warning for neuropsychiatric events. Its side effects are not asked.
Current guidelines differ: steroidsSlide 89: taper after more than 5 days (Dr. Wood affirmed it aloud; asked once). Short bursts for an exacerbation are usually stopped without a taper. Slide 99: intravenous steroids preferred in status asthmaticus; oral works as well when the patient can swallow.
Current guidelines differ: chronic obstructive pulmonary diseaseSince 2023 groups C and D are one group E. The varenicline (and bupropion) boxed warning was removed in 2016. Pneumococcal vaccination now usually starts with a conjugate vaccine. The slides are keyed.
Boxed warnings (not on the slides)Fluoroquinolones (tendon rupture, neuropathy, central nervous system effects), aminoglycosides (kidney, ear, neuromuscular), isoniazid (hepatitis), omalizumab (anaphylaxis). Varenicline's is the only one the slides state.